Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics' investigational new drug application for ABSK211 was cleared by China's National Medical Products Administration.
The drug candidate is for the treatment of patients with advanced solid tumors harboring KRAS alterations, according to a Wednesday Hong Kong bourse filing.